Supplementary Table S1 from Preclinical Development of the Anti-LAG-3 Antibody REGN3767: Characterization and Activity in Combination with the Anti-PD-1 Antibody Cemiplimab in Human PD-1xLAG-3–Knockin Mice
Year: 2023
Type: supplementary-materials
Abstract: Supplementary Table S1 shows results of treatment with cemiplimab and REGN3767 in in vivo tumor model
Authors: Elena Burova, Aynur Hermann, Jie Dai, Erica Ullman, Gabor Halasz, Terra Potocky, Seongwon Hong, Matt Liu, Omaira Allbritton, Amy Woodruff, Jerry Pei, Ashique Rafique, William Poueymirou, Joel Martin, Douglas MacDonald, William C. Olson, Andrew Murphy, Ella Ioffe, Gavin Thurston, Markus Mohrs
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
OpenAlex ID: W4362548189